TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25348121

Group type: EXPERIMENTAL
Intervention: 10 min conditioned stimulus (CS) during slow wave sleep (SWS)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 10 min conditioned stimulus (CS) during wakefulness
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 3 min conditioned stimulus (CS) during SWS
Number of subjects: 96

Group type: COMPARATOR
Intervention: 10 min irrelevant tone (control stimulus, CtrS) during SWS
Number of subjects: 96

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 96
Study: 23533252

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 0.375% bupivacaine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 19
Study: 21040167

Group type: EXPERIMENTAL
Intervention: Post-transplantation dosing guided by a 2-hour (C(2) ) level (T2 group)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard dosing (control group)
Number of subjects: 84
Study: 18369537

Group type: EXPERIMENTAL
Intervention: Dorzolamide b.i.d. (08.00 and 20.00)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dorzolamide t.i.d. (08.00, 16.00 and 20.00)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dorzolamide t.i.d. (18.00)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dorzolamide b.i.d. (18.00)
Number of subjects: 15
Study: 17053765

Group type: EXPERIMENTAL
Intervention: Phlebodia 600
Number of subjects: 30
Study: 14575375

Group type: EXPERIMENTAL
Intervention: 99mTc HMPAO lung scan
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy men)
Number of subjects: 20
Study: 11305226

Group type: EXPERIMENTAL
Intervention: Intraoral appliance therapy (daily use) during Phase I (6 months) and Phase II (6 months)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intraoral appliance therapy (daily use) during Phase II (6 months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control period (6 months prior to treatment)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Phase I and Phase II of intraoral appliance therapy
Number of subjects: 20
Study: 9392574

Group type: EXPERIMENTAL
Intervention: Entacapone 200 mg
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 7949185

Group type: EXPERIMENTAL
Intervention: Standard Risk Group (SRG) with reinduction therapy
Number of subjects: 998

Group type: COMPARATOR
Intervention: Standard Risk Group (SRG) without reinduction therapy
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Risk Group (RG)
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Experimental Group (EG)
Number of subjects: 998

Group type: COMPARATOR
Intervention: Late intensification in Risk Group (RG)
Number of subjects: 998

Group type: COMPARATOR
Intervention: Prednisone poor response
Number of subjects: 998
Study: 3190994

Group type: EXPERIMENTAL
Intervention: Single oral dose of 20 mg pholcodine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Single oral dose of 60 mg pholcodine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Chronic administration of 20 mg pholcodine 8 hourly for 10 days
Number of subjects: 6
Study: 30946381

Group type: EXPERIMENTAL
Intervention: Ropivacaine group (0.5% ropivacaine, 40 mL, n=69)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (no analgesic, n=63)
Number of subjects: 132
Study: 28968871

Group type: EXPERIMENTAL
Intervention: Quadrivalent recombinant influenza vaccine (RIV4)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-dose, egg‐grown, quadrivalent‐inactivated influenza vaccine (IIV4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both RIV4 and IIV4
Number of subjects: 0
Study: 25304132

Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg subcutaneously every 2 weeks for 12 weeks
Number of subjects: 111
Study: 23294343

Group type: EXPERIMENTAL
Intervention: Handwashing promotion
Number of subjects: 461

Group type: COMPARATOR
Intervention: Control
Number of subjects: 461
Study: 21630116

Group type: EXPERIMENTAL
Intervention: Pentax‐AWS
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: GlideScope
Number of subjects: 32

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 32
Study: 19175188

Group type: EXPERIMENTAL
Intervention: Video-tape viewing
Number of subjects: 91

Group type: COMPARATOR
Intervention: Teaching booklet
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both groups (video-tape and teaching booklet)
Number of subjects: 91
Study: 16861255

Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide + 8 mg dexamethasone
Number of subjects: 3140

Group type: EXPERIMENTAL
Intervention: 25 mg metoclopramide + 8 mg dexamethasone
Number of subjects: 3140

Group type: EXPERIMENTAL
Intervention: 50 mg metoclopramide + 8 mg dexamethasone
Number of subjects: 3140

Group type: COMPARATOR
Intervention: 0 mg metoclopramide + 8 mg dexamethasone
Number of subjects: 3140
Study: 12508269

Group type: EXPERIMENTAL
Intervention: Short, intensive therapy (CCG-5911)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Moderate-dose chemotherapy (previous studies)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Elevated LDH (> or = 500 IU/L) at diagnosis and young age (<5 years)
Number of subjects: 279
Study: 10685739

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg for 6 weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Famotidine (40 mg for 6 weeks)
Number of subjects: 17
Study: 9376181

Group type: EXPERIMENTAL
Intervention: Formestane (250 mg intramuscularly biweekly)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Megestrol acetate (160 mg orally daily)
Number of subjects: 179
Study: 8227233

Group type: EXPERIMENTAL
Intervention: 100 mg conventional metoprolol (M100)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50 or 100 mg slow-release metoprolol CR (CR50, CR100)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30846557

Group type: EXPERIMENTAL
Intervention: Tenapanor (3 mg)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Tenapanor (10 mg)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Tenapanor (30 mg, down-titrated)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Pooled Tenapanor group
Number of subjects: 219
Study: 29146660

Group type: EXPERIMENTAL
Intervention: Behaviour change intervention consisting of four physical activity consultations with a physiotherapist, supported by a handbook and pedometer.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care only (control group).
Number of subjects: 60
Study: 25772512

Group type: EXPERIMENTAL
Intervention: Standardized therapy with traditional Chinese medicine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Individualized therapy with traditional Chinese medicine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Best supportive care with traditional Chinese medicine
Number of subjects: 24

Group type: COMPARATOR
Intervention: NCCN NSCLC treatment guidelines (Control group)
Number of subjects: 24
Study: 22743641

Group type: EXPERIMENTAL
Intervention: Cortoss
Number of subjects: 256

Group type: COMPARATOR
Intervention: PMMA
Number of subjects: 256
Study: 21532952

Group type: EXPERIMENTAL
Intervention: Bright light treatment (2000, 4000, or 8000 lux for 1, 2, or 3 hours)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Moderate intensity light (2000 lux)
Number of subjects: 56
Study: 18954199

Group type: EXPERIMENTAL
Intervention: Red color
Number of subjects: 5

Group type: COMPARATOR
Intervention: Other achromatic and chromatic colors
Number of subjects: 5
Study: 16186461

Group type: EXPERIMENTAL
Intervention: Minimal intervention physical activity strategy (PACE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard physical activity advice (Control)
Number of subjects: 0
Study: 12895189

Group type: EXPERIMENTAL
Intervention: 800 mg ibuprofen (single oral dose)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 32
Study: 10218357

Group type: EXPERIMENTAL
Intervention: Brandt's double cuff-tubes (Group 2)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Standard low-pressure tubes (Group 1)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (Group 3)
Number of subjects: 116
Study: 8669404

Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (no supplementation)
Number of subjects: 45
Study: 1989743

Group type: EXPERIMENTAL
Intervention: Interpleural bupivacaine-adrenaline mixture
Number of subjects: 42

Group type: COMPARATOR
Intervention: Intramuscular meperidine
Number of subjects: 42
Study: 6613477

Group type: EXPERIMENTAL
Intervention: Intraperitoneal drain (187 patients)
Number of subjects: 383

Group type: COMPARATOR
Intervention: No intraperitoneal drain (196 patients)
Number of subjects: 383
Study: 30948449

Group type: EXPERIMENTAL
Intervention: Arachidonic acid (AA)
Number of subjects: 270342

Group type: EXPERIMENTAL
Intervention: α-linolenic acid
Number of subjects: 270342
Study: 28089728

Group type: EXPERIMENTAL
Intervention: Clinical with dermoscopic teleconsultation
Number of subjects: 454

Group type: COMPARATOR
Intervention: Clinical teleconsultations (CTC)
Number of subjects: 454
Study: 26562047

Group type: EXPERIMENTAL
Intervention: Peer group‐based intervention group (IG)
Number of subjects: 543

Group type: COMPARATOR
Intervention: Self‐management control group (CG)
Number of subjects: 543
Study: 24170751

Group type: EXPERIMENTAL
Intervention: Intensive diabetes treatment
Number of subjects: 657

Group type: COMPARATOR
Intervention: Conventional diabetes treatment
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: Insulin dosage increase (10 units/day)
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: BMI increase (kg/m²)
Number of subjects: 657
Study: 22661508

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day) for 1 month in statin-naïve patients
Number of subjects: 13

Group type: COMPARATOR
Intervention: Simvastatin in crossover study
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 13
Study: 19307970

Group type: EXPERIMENTAL
Intervention: 0.1 mg morphine
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: 0.2 mg morphine
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: 0.1 mg and 0.2 mg morphine
Number of subjects: 188
Study: 17326830

Group type: EXPERIMENTAL
Intervention: Psychiatric consultation embedded in a training programme
Number of subjects: 60

Group type: COMPARATOR
Intervention: Care As Usual (only training aimed at recognition)
Number of subjects: 60
Study: 15185764

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Endovascular stent treatment
Number of subjects: 565

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 565
Study: 11806217

Group type: EXPERIMENTAL
Intervention: Structum (chondroitin sulphate)
Number of subjects: 555

Group type: COMPARATOR
Intervention: Control (matched patients)
Number of subjects: 555
Study: 9571294

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 7974588

Group type: EXPERIMENTAL
Intervention: NASCET method
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: ECST method
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: CC method
Number of subjects: 112
Study: 3382462

Group type: EXPERIMENTAL
Intervention: 40 mg nimodipine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 60 mg nimodipine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31438581

Group type: EXPERIMENTAL
Intervention: Problematic cannabis use (measured by CAST scores)
Number of subjects: 648

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 648
Study: 28534723

Group type: EXPERIMENTAL
Intervention: Jugular venipuncture alpaca model (group M; n=18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (group C; n=18)
Number of subjects: 36
Study: 26415790

Group type: EXPERIMENTAL
Intervention: Wenxin Keli
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study: 23910069

Group type: EXPERIMENTAL
Intervention: Mivacurium 0.25 mg·kg(‐1) (NMB group)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Saline solution (NoNMB group)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: NMB group
Number of subjects: 38

Group type: COMPARATOR
Intervention: NoNMB group
Number of subjects: 38
Study: 21911782

Group type: EXPERIMENTAL
Intervention: Genetic variant TLL1 rs1503298
Number of subjects: 1043
Study: 19918588

Group type: EXPERIMENTAL
Intervention: Zirconia-ceramic FDPs
Number of subjects: 59

Group type: COMPARATOR
Intervention: Metal-ceramic FDPs
Number of subjects: 59
Study: 16377964

Group type: EXPERIMENTAL
Intervention: 0.6 g/kg of alcohol preload
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.3 g/kg of alcohol preload
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo preload
Number of subjects: 15
Study: 12843164

Group type: EXPERIMENTAL
Intervention: DHEA supplementation (25 mg/d)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10639301

Group type: COMPARATOR
Intervention: High dose amiodarone
Number of subjects: 1073

Group type: COMPARATOR
Intervention: Low dose amiodarone
Number of subjects: 1073

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 1073
Study: 8878569

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-coated triple-lumen catheters
Number of subjects: 254

Group type: COMPARATOR
Intervention: Uncoated control catheters
Number of subjects: 254
Study: 1505605

Group type: EXPERIMENTAL
Intervention: Computer-assisted dosing of theophylline (437 mg loading dose)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (unaided physicians dosing of theophylline, 167 mg loading dose)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Computer-assisted dosing of theophylline (613 mg loading dose for patients not previously on theophylline)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (200 mg loading dose for patients not previously on theophylline)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both groups (computer-assisted and control)
Number of subjects: 25
Study: 6381556

Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride at a dosage of 150 mg at bedtime
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31168959

Group type: EXPERIMENTAL
Intervention: Influencer marketing of an unhealthy snack with advertising disclosure (n = 50)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Influencer marketing of an unhealthy snack without advertising disclosure (n = 50)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (influencer marketing of a non-food product) (n = 51)
Number of subjects: 151
Study: 31473805

Group type: EXPERIMENTAL
Intervention: Ecc‐vBFR (n=12)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Con‐vBFR (n=13)
Number of subjects: 25
Study: 27980864

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field with nerve and tendon gliding exercises, three times per week for four weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pulsed ultrasound with the same wrist exercises
Number of subjects: 40
Study: 25445859

Group type: EXPERIMENTAL
Intervention: benralizumab (0.3 mg/kg and 1.0 mg/kg)
Number of subjects: 110

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 110
Study: 24071578

Group type: EXPERIMENTAL
Intervention: Single 400-mg oral dose of ribavirin
Number of subjects: 24
Study: 20962657

Group type: EXPERIMENTAL
Intervention: Airway Scope (AWS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 70
Study: 19625981

Group type: EXPERIMENTAL
Intervention: Social Effectiveness Therapy for Children
Number of subjects: 88
Study: 17261405

Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD)
Number of subjects: 3998

Group type: COMPARATOR
Intervention: No Chronic Kidney Disease (CKD)
Number of subjects: 3998

Group type: EXPERIMENTAL
Intervention: Diastolic Heart Failure (LVEF >45%) with CKD
Number of subjects: 3998

Group type: EXPERIMENTAL
Intervention: Systolic Heart Failure (LVEF ≤45%) with CKD
Number of subjects: 3998

Group type: EXPERIMENTAL
Intervention: LVEF <35% with CKD
Number of subjects: 3998

Group type: EXPERIMENTAL
Intervention: LVEF 35% to 55% with CKD
Number of subjects: 3998

Group type: EXPERIMENTAL
Intervention: LVEF >55% with CKD
Number of subjects: 3998
Study: 15541237

Group type: EXPERIMENTAL
Intervention: Self-expanding stent after beta-VBT
Number of subjects: 27

Group type: COMPARATOR
Intervention: Self-expanding stent alone
Number of subjects: 27
Study: 11995261

Group type: EXPERIMENTAL
Intervention: Inhaled heparin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 9728845

Group type: EXPERIMENTAL
Intervention: IV amino acid infusion at the rate of 126 mL/h throughout anesthesia
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nutrient‐free saline infusion
Number of subjects: 14
Study: 8665279

Group type: EXPERIMENTAL
Intervention: Leuko Ankle brace
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nessa Ankle brace
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (no brace)
Number of subjects: 13
Study: 3177911

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 105

Group type: COMPARATOR
Intervention: Regional anesthesia
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: General anesthesia and Regional anesthesia
Number of subjects: 105
Study: 31647185

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA treatment (400 U at 12-week intervals)
Number of subjects: 296
Study: 30342297

Group type: EXPERIMENTAL
Intervention: FDC polypill (atenolol, ramipril, hydrochlorothiazide, and a statin)
Number of subjects: 5713

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 5713

Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 5713

Group type: EXPERIMENTAL
Intervention: Combined effect of aspirin and the Polycap
Number of subjects: 5713

Group type: COMPARATOR
Intervention: Placebo (for aspirin and vitamin D)
Number of subjects: 5713
Study: 28103904

Group type: EXPERIMENTAL
Intervention: Fruquintinib plus best supportive care (BSC)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo plus best supportive care (BSC)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Fruquintinib (phase Ib study)
Number of subjects: 113
Study: 26185179

Group type: EXPERIMENTAL
Intervention: 25 mg ephedrine, twice daily
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 23510972

Group type: EXPERIMENTAL
Intervention: Interactive Structured Rich-Media guidelines (ISRMGs) on mobile phones
Number of subjects: 50

Group type: COMPARATOR
Intervention: Paper-based guidelines
Number of subjects: 50
Study: 21211686

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 360

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 360
Study: 19098618

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 90

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 90
Study: 16814218

Group type: EXPERIMENTAL
Intervention: Obese women who gained 40 or more pounds during pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total pregnancy weight gain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infant birthweight
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intrapartum care measures and labor events
Number of subjects: 0
Study: 12736880

Group type: EXPERIMENTAL
Intervention: Exercise group (14 months of vigorous, combined high-impact, strength, and endurance training)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 11003446

Group type: EXPERIMENTAL
Intervention: Grass-pollen immunotherapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Birch-pollen immunotherapy
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 52
Study: 9087388

Group type: EXPERIMENTAL
Intervention: Intralesional injections of lymphokine-activated killer (LAK) cells (2 to 9 x 10^8) and recombinant interleukin-2 (rIL-2) (10^6 IU) weekly for four cycles, plus subcutaneous rIL-2 (3 x 10^6 IU/day for 24 days)
Number of subjects: 9
Study: 7968328

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg sublingual)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Nifedipine and Control group
Number of subjects: 33
Study: 6117466

Group type: EXPERIMENTAL
Intervention: Strophanthin (0.5 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Practolol (10 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propranolol (4 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Strophanthin compared to β-blockers (Practolol and Propranolol)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Practolol and Propranolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All drugs (Strophanthin, Practolol, Propranolol)
Number of subjects: 10
Study: 31336450

Group type: EXPERIMENTAL
Intervention: Vitamin D plus physical activity
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 28816136

Group type: EXPERIMENTAL
Intervention: Music Therapy (MT)
Number of subjects: 78

Group type: COMPARATOR
Intervention: No Music Therapy (no-MT)
Number of subjects: 78
Study: 26017676

Group type: EXPERIMENTAL
Intervention: Unconditional Cash Transfer (UCT)
Number of subjects: 5331

Group type: EXPERIMENTAL
Intervention: Conditional Cash Transfer (CCT)
Number of subjects: 5331

Group type: COMPARATOR
Intervention: Control
Number of subjects: 5331

Group type: EXPERIMENTAL
Intervention: Household Assets
Number of subjects: 5331
Study: 23577700

Group type: EXPERIMENTAL
Intervention: Antenatal care package with reduced visits
Number of subjects: 12568

Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 12568